Brief: Gensight Biologics Reaches Deal With ANSM For Opening Of Lumevoq Early Access Program In France
12/06/2025 18:27
June 12 (Reuters) - Gensight Biologics SA SIGHT.PA: GENSIGHT BIOLOGICS REACHES AGREEMENT WITH ANSM FOR OPENING OF LUMEVOQ® NAMED EARLY ACCESS PROGRAM (AAC) IN FRANCE GENSIGHT BIOLOGICS SA - TARGETS Q3 2025 FOR FINALIZING DOSE-RANGING STUDY PROTOCOL GENSIGHT BIOLOGICS SA - AAC PROGRAM TARGETED TO OPEN IN Q4 2025 Source text: ID:nBw32Cm9Qa Further company coverage: SIGHT.PA
Recent news on Gensight Biologics SA
See all newsHealth Rounds: Blindness treatment based on Nobel-winning research shows promise
France's GenSight Biologics H1 net loss widens on higher R&D expenses
Brief: GenSight Biologics H1 Net Income EUR -10.3 Million
France's GenSight Biologics 2025 net loss narrows on reduced R&D spending
Brief: GenSight Biologics FY EPS EUR -0.08